PRIOR AUTHORIZATION REQUEST FORM

EOC ID:

Ibrance

Phone: 800-728-7947 Fax back to: 866-880-4532

The Scott & White Health Plan Pharmacy Department manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. **Please note any information left blank or illegible may delay the review process.**

Patient Name:	**Prescriber Name:** **Supervising Physician:**	
Member/Subscriber Number:	Fax:	Phone:
Date of Birth:	Office Contact:	
Group Number:	NPI:	State Lic ID:
Address:	Address:	
City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name (if applicable):	

Drug Name and Strength:

Directions / SIG:

Please attach any pertinent medical history or information for this patient that may support approval. Please answer the following questions and sign.

Q1. Please provide ICD code(s) for diagnosis.

Q2. For which diagnosis is Ibrance (palbociclib) being prescribed?

☐ Advanced or metastatic breast cancer
☐ Other (please specify)

Q3. Is prescribing physician a Hematology or Oncology specialist?

☐ Yes ☐ No

Q4. Is the patient hormone receptor (HR) POSITIVE?

☐ Yes ☐ No

Q5. Is the patient human epidermal growth factor receptor 2 (HER2) NEGATIVE?

☐ Yes ☐ No

Q6. Will Ibrance (palbociclib) be used in combination with letrozole?

☐ Yes ☐ No

Q7. Is the patient postmenopausal?

PRIOR AUTHORIZATION REQUEST FORM

EOC ID:

Ibrance

Phone: 800-728-7947 Fax back to: 866-880-4532

The Scott & White Health Plan Pharmacy Department manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. **Please note any information left blank or illegible may delay the review process.**

Patient Name:	**Prescriber Name:** **Supervising Physician:**

☐ Yes ☐ No
Q8. Will Ibrance (palbociclib) be used in combination with fulvestrant? ☐ Yes ☐ No
Q9. Has patient had disease progression following endocrine therapy? ☐ Yes ☐ No
Q10. If you selected "no" to any of the questions above, please provide documentation that use is consistent with a category 1 or higher recommendation per NCCN compendia or guidelines.
Q11. Additional Comments

Prescriber Signature

Date

□ Expedited/Urgent - By checking this box and signing above, I certify that applying the standard review timeframe may seriously jeopardize the life or health of the enrollee or the enrollee's ability to regain maximum function

Lack of the necessary documentation may result in a medical necessity denial. Requesting providers may speak to a SWHP pharmacist or medical director at 1-800-728-7947 regarding the case to have an opportunity to help impact the decision on a request before coverage has been decided.